bioAffinity Technologies (NASDAQ:BIAF) Raised to “Hold” at Wall Street Zen

bioAffinity Technologies (NASDAQ:BIAF) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of bioAffinity Technologies in a research note on Monday, July 20th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

bioAffinity Technologies Stock Performance

Shares of NASDAQ BIAF opened at $0.66 on Friday. The firm has a fifty day moving average price of $1.14 and a 200-day moving average price of $1.69. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.36 and a quick ratio of 1.34. The stock has a market cap of $3.13 million, a PE ratio of -0.06 and a beta of -1.11. bioAffinity Technologies has a 1 year low of $0.61 and a 1 year high of $13.50.

bioAffinity Technologies (NASDAQ:BIAF) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($2.40) by $1.59. bioAffinity Technologies had a negative net margin of 280.53% and a negative return on equity of 285.75%. The firm had revenue of $1.35 million for the quarter, compared to the consensus estimate of $1.48 million.

Institutional Investors Weigh In On bioAffinity Technologies

Institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC bought a new stake in shares of bioAffinity Technologies during the fourth quarter valued at approximately $36,000. Scientech Research LLC bought a new position in shares of bioAffinity Technologies during the third quarter worth $49,000. Finally, J. Safra Sarasin Holding AG bought a new position in shares of bioAffinity Technologies during the first quarter worth $164,000. 1.64% of the stock is owned by hedge funds and other institutional investors.

About bioAffinity Technologies

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.